Rubedo reports promising early trial results for anti-aging skin cream

Rubedo Life Sciences reported preliminary Phase 1b/2a data showing topical RLS-1496 1% cream produced a 46% reduction in actinic keratosis lesion count at four weeks in the first 18 of 24 patients evaluated, versus an 11% reduction in untreated controls. The open-label, multicenter U.S. trial assess…